Shares of TG Therapeutics Inc. plunged 44.3 percent to $5.15 on Tuesday as uncertainty over timing of a key interim readout for its two-drug chronic lymphocytic leukemia (CLL) treatment led it to scrub plans to seek accelerated approval for the combo.